It is with immense pride that the Predictive Oncology team, already labeled by the Ligue Contre le Cancer since 2018, sees its label renewed for the period 2025-2027. This renewal testifies to the quality and importance of the work carried out by the team in the fight against cancer, as well as to the confidence placed in them by the League.

Support from the Ligue Contre le Cancer enables the team to pursue its groundbreaking research into drug-conjugated antibody (DCA) resistance. These targeted treatments represent a major advance for patients with metastatic breast or colon cancer.

The team would like to express its gratitude to the Ligue Contre le Cancer for its unfailing support, which is helping to speed up scientific advances and improve cancer care.